Meeting
2015 ASCO Annual Meeting
A phase Ib study of BBI608 in combination with FOLFIRI with and without bevacizumab in patients (pts) with advanced colorectal cancer (CRC).
Authors
Joleen Marie Hubbard
Mayo Clinic, Rochester, MN
Joleen Marie Hubbard , Derek J. Jonker , Bert H. O'Neil , Thorvardur Ragnar Halfdanarson , Axel Grothey , Youzhi Li , Laura Borodyansky , Chiang Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT02024607
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3616)
DOI
10.1200/jco.2015.33.15_suppl.3616
Abstract #
3616
Poster Bd #
109
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).
First Author: Bert H. O'Neil
Poster
2017 Gastrointestinal Cancers Symposium
Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).
First Author: Johanna C. Bendell
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase Ia/Ib, open-label, dose escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy (CT) in patients (pts) with advanced GI cancers.
First Author: Scott Kopetz
Poster
2019 Gastrointestinal Cancers Symposium
NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer.
First Author: T.R. Jeffry Evans